Literature DB >> 2643283

Effects of nicardipine on blood pressure and renal function in elderly hypertensive patients with renal dysfunction.

T Saruta1.   

Abstract

The effects of monotherapy with nicardipine, 20 mg three times a day, have been investigated in a 1-year study of 26 elderly (greater than 60 years) patients with hypertension with various types of renal dysfunction and seven without renal dysfunction. Parameters measured included blood pressure, blood chemistry (serum creatinine, uric acid, blood urea nitrogen, blood glucose total cholesterol, and electrolytes), plasma renin activity, and plasma aldosterone concentration. Nicardipine was effective in reducing blood pressure in all patients with diabetic nephropathy, parenchymal renal diseases, or hypertensive nephropathy, and in those without renal dysfunction. Serum creatinine and blood urea nitrogen levels were slightly elevated in some patients whose pretreatment serum creatinine level was greater than 2 mg/dl, regardless of the type of nephropathy. However, it was not determined whether this effect was the result of a reduction in blood pressure induced by nicardipine. Serum sodium, potassium, total cholesterol, and blood glucose levels were unchanged by the administration of nicardipine. Changes in plasma renin activity and aldosterone levels were not significant. These results suggest that nicardipine can be used safely in elderly patients with hypertension with renal dysfunction, regardless of the type of nephropathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643283     DOI: 10.1016/0002-8703(89)90691-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

Review 1.  Nicardipine. A review of its pharmacology and therapeutic efficacy in older patients.

Authors:  J E Frampton; D Faulds
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

2.  Biochemical changes during amlodipine treatment in hypertensive patients.

Authors:  J E Ahaneku; G O Taylor; O Walker; E O Agbedana; A Sowunmi; L A Salako
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.